Evocalcet

Evocalcet (trade name Orkedia) is a drug for the treatment of hyperparathyroidism.[1] It acts as a calcium-sensing receptor agonist.[2]

Evocalcet
Clinical data

Trade names	Orkedia
Identifiers
IUPAC name 2-[4-[(3S)-3-[[(1R)-1-Naphthalen-1-ylethyl]amino]pyrrolidin-1-yl]phenyl]acetic acid
CAS Number	870964-67-3
PubChem CID	71242808
DrugBank	DB12388
UNII	E58MLH082P
KEGG	D11063
Chemical and physical data
Formula	C₂₄H₂₆N₂O₂
Molar mass	374.484 g·mol⁻¹

In 2018, it was approved in Japan for treatment of secondary hyperparathyroidism in patients on dialysis.[3]

References

Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, Shoukei Y, et al. (2018). "A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro". PLOS ONE. 13 (4): e0195316. Bibcode:2018PLoSO..1395316K. doi:10.1371/journal.pone.0195316. PMC 5882164. PMID 29614098.
Miyazaki H, Ikeda Y, Sakurai O, Miyake T, Tsubota R, Okabe J, et al. (June 2018). "Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism". Bioorganic & Medicinal Chemistry Letters. 28 (11): 2055–2060. doi:10.1016/j.bmcl.2018.04.055. PMID 29724589.
"Kyowa Hakko Kirin Launches Orkedia Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan" (Press release). Kyowa Hakko Kirin. May 22, 2018.

Calcium homeostasis (H05)

Parathyroid hormone and analogues

Anti-parathyroid hormone agents

Calcitonin derivatives	Calcitonin Elcatonin
Calcimimetics	Cinacalcet Etelcalcetide
Vitamin D analogues	Calcifediol Calcitriol Cholecalciferol Doxercalciferol Ergocalciferol Paricalcitol

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.